Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314403 · ClinicalTrials.gov registry record · Phase 1
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02314403: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02314403 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02314403, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Interventions
- DRUG Rituximab
- RADIATION Total Body Irradiation
- DRUG ATG
- DRUG Belatacept
- RADIATION Thymic Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314403
The ClinicalTrials.gov registry entry for NCT02314403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT02314403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314403 about?
NCT02314403 is a clinical study titled "Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)". This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked...
What is the current status of trial NCT02314403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-02. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02314403?
The interventions under investigation include: Rituximab (DRUG), Total Body Irradiation (RADIATION), ATG (DRUG), Belatacept (DRUG), Thymic Irradiation (RADIATION).
Who is sponsoring clinical trial NCT02314403?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.